Vericel Corporation (VCEL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vericel Corporation (VCEL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

58.63

-0.99 (-1.66%)

At close: Jan 14, 2025, 3:59 PM

52.10

-11.14%

After-hours Jan 14, 2025, 07:59 PM EST

undefined% (undefined)

Bid	52.11
Market Cap	2.89B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.08
PE Ratio (ttm)	732.88
Forward PE	n/a
Analyst	Buy

Ask	54.3
Volume	397,236
Avg. Volume (20D)	387,724
Open	60.76
Previous Close	59.62
Day's Range	56.71 - 60.93
52-Week Range	37.35 - 61.49
Beta	undefined

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epic...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 4, 1997

Employees 314

Stock Exchange NASDAQ

Ticker Symbol VCEL

Website https://vcel.com

Analyst Forecast

According to 6 analyst ratings, the average rating for VCEL stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 2.34% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Vericel Corporation is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $80.82M, reflecting a 24.35% YoY growth and earnings per share of 0.31, making a 19.23% increase YoY.

Why Price Moved

5 hours ago · Source New

Vericel shares are trading lower after the company... Unlock content with Pro Subscription

20 hours ago · Source New

-1.59%

Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.

News

3 weeks ago · seekingalpha.com

Vericel Corporation: Hard To Justify Current Valuation

Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 r...

1 month ago · investors.com

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

2 months ago · zacks.com

Here's Why Momentum in Vericel (VCEL) Should Keep going

Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh...

2 months ago · seekingalpha.com

Vericel Corporation (VCEL) Q3 2024 Earnings Conference Call Transcript

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executi...

2 months ago · zacks.com

Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.